Analysis Article • Aug 23
Have your own idea? Try our Stock Screener
Hong Kong (HSI) Biotech Industry Analysis
UpdatedAug 25, 2026
DataAggregated Company Financials
Companies67
- 7D-1.1%
- 3M-3.6%
- 1Y-27.6%
- YTD-10.7%
Over the last 7 days, the Biotech industry has risen 1.0%, driven by gains from Innovent Biologics of 4.4%. Meanwhile, RemeGen actually underperformed within the industry, shrinking 8.3% in the last week. In contrast, the industry has lost 26% in the last 12 months. As for the next few years, earnings are expected to grow by 29% per annum.
Industry Valuation and Performance
Has the Hong Kong Biotech Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
|---|---|---|---|---|---|---|
| Tue, 25 Aug 2026 | HK$934.6b | HK$97.5b | -HK$1,083,046,900.93 | 26.2x | -863x | 9.6x |
| Thu, 23 Jul 2026 | HK$927.5b | HK$94.5b | -HK$4,121,692,727.30 | 20.4x | -225x | 9.8x |
| Sat, 20 Jun 2026 | HK$818.2b | HK$94.7b | -HK$4,481,484,096.33 | 17.5x | -182.6x | 8.6x |
| Mon, 18 May 2026 | HK$949.9b | HK$94.1b | -HK$3,911,703,893.44 | 21.6x | -242.8x | 10.1x |
| Wed, 15 Apr 2026 | HK$1.1t | HK$93.1b | -HK$3,932,013,296.64 | 28.6x | -277.7x | 11.7x |
| Fri, 13 Mar 2026 | HK$951.1b | HK$72.7b | -HK$12,108,204,907.75 | 49.3x | -78.5x | 13.1x |
| Sun, 08 Feb 2026 | HK$945.5b | HK$70.5b | -HK$14,017,336,394.37 | 34.9x | -67.5x | 13.4x |
| Tue, 06 Jan 2026 | HK$963.9b | HK$70.1b | -HK$13,849,681,950.35 | 37x | -69.6x | 13.7x |
| Thu, 04 Dec 2025 | HK$999.5b | HK$69.4b | -HK$12,939,758,153.49 | 40.1x | -77.2x | 14.4x |
| Sat, 01 Nov 2025 | HK$1.0t | HK$68.7b | -HK$12,803,200,100.19 | 43.9x | -79x | 14.7x |
| Mon, 29 Sep 2025 | HK$1.1t | HK$68.3b | -HK$13,073,348,319.87 | 46.9x | -82.2x | 15.7x |
| Wed, 27 Aug 2025 | HK$1.1t | HK$63.0b | -HK$13,214,208,969.52 | 54.9x | -82.8x | 17.4x |
| Fri, 25 Jul 2025 | HK$928.2b | HK$63.9b | -HK$12,553,304,197.70 | 38x | -73.9x | 14.5x |
| Sun, 22 Jun 2025 | HK$704.3b | HK$62.2b | -HK$12,084,195,438.59 | 32.5x | -58.3x | 11.3x |
| Tue, 20 May 2025 | HK$572.0b | HK$61.6b | -HK$11,847,407,806.46 | 30.5x | -48.3x | 9.3x |
| Thu, 17 Apr 2025 | HK$519.3b | HK$60.2b | -HK$12,115,696,645.42 | 27.8x | -42.9x | 8.6x |
| Sat, 15 Mar 2025 | HK$458.3b | HK$52.7b | -HK$16,871,210,501.23 | 22.6x | -27.2x | 8.7x |
| Mon, 10 Feb 2025 | HK$377.0b | HK$52.0b | -HK$17,298,881,792.01 | 13.7x | -21.8x | 7.2x |
| Wed, 08 Jan 2025 | HK$362.8b | HK$51.7b | -HK$17,176,165,660.39 | 11.8x | -21.1x | 7x |
| Fri, 06 Dec 2024 | HK$396.5b | HK$52.1b | -HK$17,335,762,222.20 | 10.9x | -22.9x | 7.6x |
| Sun, 03 Nov 2024 | HK$390.7b | HK$52.9b | -HK$17,788,453,167.47 | 11.3x | -22x | 7.4x |
| Tue, 01 Oct 2024 | HK$411.8b | HK$53.0b | -HK$18,412,369,336.92 | 12.4x | -22.4x | 7.8x |
| Thu, 29 Aug 2024 | HK$332.4b | HK$53.5b | -HK$18,392,442,164.93 | 15.2x | -18.1x | 6.2x |
| Sat, 27 Jul 2024 | HK$314.0b | HK$49.7b | -HK$19,476,048,887.59 | 11.7x | -16.1x | 6.3x |
| Mon, 24 Jun 2024 | HK$332.5b | HK$49.7b | -HK$19,449,051,702.56 | 11.4x | -17.1x | 6.7x |
| Wed, 22 May 2024 | HK$361.7b | HK$49.8b | -HK$19,368,355,572.35 | 12.2x | -18.7x | 7.3x |
| Fri, 19 Apr 2024 | HK$322.4b | HK$49.6b | -HK$19,911,350,266.52 | 10.8x | -16.2x | 6.5x |
| Sun, 17 Mar 2024 | HK$366.5b | HK$47.2b | -HK$20,445,921,301.34 | 17.6x | -17.9x | 7.8x |
| Tue, 13 Feb 2024 | HK$321.6b | HK$46.8b | -HK$20,175,287,948.53 | 15.6x | -15.9x | 6.9x |
| Thu, 11 Jan 2024 | HK$382.9b | HK$46.9b | -HK$20,242,897,600.00 | 18x | -18.9x | 8.2x |
| Sat, 09 Dec 2023 | HK$399.9b | HK$46.9b | -HK$20,242,488,582.00 | 17.7x | -19.8x | 8.5x |
| Mon, 06 Nov 2023 | HK$413.3b | HK$45.2b | -HK$18,919,413,159.00 | 12.9x | -21.8x | 9.2x |
| Wed, 04 Oct 2023 | HK$400.6b | HK$45.0b | -HK$19,139,886,127.00 | 13.7x | -20.9x | 8.9x |
| Fri, 01 Sep 2023 | HK$390.1b | HK$43.5b | -HK$16,489,702,446.00 | 15x | -23.7x | 9x |
Price to Earnings Ratio
-23.7x
Current Industry PE
- Investors are relatively neutral on the Hong Kong Biotechs industry at the moment, indicating that they anticipate long term growth rates to remain steady.
- The industry is trading close to its 3-year average PS ratio of 9.9x.
Past Earnings Growth
- The earnings for companies in the Biotechs industry have improved over the last three years.
- Revenues for these companies have grown 31% per year.
- This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Hong Kong Healthcare industry?
| HK Market | 1.35% | |
| Healthcare | 1.65% | |
| Biotech | -1.10% | |
| Biotech | -1.10% | |
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| 1801 Innovent Biologics | HK$99.50 | 4.4% +HK$7.2b | -0.5% | PE182.7x | |
| 6938 Suzhou Ribo Life Science | HK$61.40 | 19.9% +HK$1.7b | n/a | PS60.5x | |
| 6915 Jiangxi Institute of Biological Products | HK$18.00 | 24.4% +HK$1.1b | n/a | PE50.2x | |
| 1530 3SBio | HK$17.90 | 2.5% +HK$1.1b | -40.2% | PE4.6x | |
| 2142 HBM Holdings | HK$16.01 | 8.2% +HK$1.1b | 29.2% | PE19.4x |